Immuron to Commence US Non-Deal Institutional Investor Roadshow
June 19 2019 - 8:00AM
Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian
biopharmaceutical company focused on developing and commercializing
oral immunotherapeutics for the prevention and treatment of many
gut mediated pathogens, today is please to release to shareholders
and investors its latest Company Update presentation ahead of a
comprehensive roadshow to investment institutions, analysts and
shareholders in the United States, by-CEO Dr. Gary Jacob.
ABOUT IMMURON:Immuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory
mediated and infectious diseases. Immuron has a novel and safe
technology platform with one commercial asset Travelan® generating
revenue. Immuron’s lead clinical candidate, IMM-124E, is presently
in Phase II trials in Severe Alcoholic Hepatitis (SAH) and
Paediatric Non-alcoholic Fatty Liver Disease (NAFLD). The company
now has plans to develop a U.S. registration dossier for IMM-124E
for Travelers’ Diarrhea. Immuron’s second clinical-stage asset,
IMM-529, targets Clostridium difficile Infections (CDI), and is
presently in a clinical trial in CDI patients. These products
together with the Company’s other preclinical immunotherapy
pipeline products currently under development targeting
immune-related and infectious diseases are anticipated to meet
pressing needs in the global immunotherapy market.
For more information visit:
http://www.immuron.com
FORWARD-LOOKING STATEMENTS:
This press release may contain “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Such statements include, but are not limited
to, any statements relating to our growth strategy and product
development programs and any other statements that are not
historical facts. Forward-looking statements are based on
management’s current expectations and are subject to risks and
uncertainties that could negatively affect our business, operating
results, financial condition and stock value. Factors that could
cause actual results to differ materially from those currently
anticipated include: risks relating to our growth strategy; our
ability to obtain, perform under and maintain financing and
strategic agreements and relationships; risks relating to the
results of research and development activities; risks relating to
the timing of starting and completing clinical trials;
uncertainties relating to preclinical and clinical testing; our
dependence on third-party suppliers; our ability to attract,
integrate and retain key personnel; the early stage of products
under development; our need for substantial additional funds;
government regulation; patent and intellectual property matters;
competition; as well as other risks described in our SEC filings.
We expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in our expectations or any
changes in events, conditions or circumstances on which any such
statement is based, except as required by law.
A presentation accompanying this announcement
can be found
at: https://www.globenewswire.com/NewsRoom/AttachmentNg/88d17e27-6d8e-4d46-ba8a-4b237f54caac
COMPANY CONTACT:
Gary S. Jacob, Ph.D.
Chief Executive Officer
Ph: +61 (0)3 9824 5254
info@immuron.com
AUS INVESTOR RELATIONS:
Peter Taylor
NWR Communications
Ph: +61 (0)4 1203 6231
peter@nwrcommunications.com.au
USA INVESTOR RELATIONS:
Dave Gentry - CEO
RedChip Companies, Inc.
US Ph: +1 (407) 491 4498
dave@redchip.com
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024